Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
*Correspondence: Xiang Jun Jiang,
This article was submitted to Gastrointestinal Cancers: Gastric and Esophageal Cancers, a section of the journal Frontiers in Oncology
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
In the original article, there were three errors in the text.
Firstly, the dissolution of H101 was incorrectly stated. A correction has been made to
“H101 (-20°C, Shanghai Sunway Biotech, Shanghai, China) was then dissolved with normal saline to 30% of the estimated tumor volume at room temperature, was peritumorally injected
Secondly, the dose of H101 for patients with one lesion with a maximum diameter of ≤5 cm was incorrectly stated. A correction has been made to
“The doses of H101 depended on tumor size and the number of lesions: (1) 0.5 × 1012 virus particles (vp)/day (1 unit) for patients with one lesion with a maximum diameter of ≤5 cm; (2) 1.0 × 1012 vp/day (2 units) for patients with one lesion with a maximum diameter of 5-10 cm or two lesions with a sum of the diameters of 5-10 cm; (3) 1.5 × 1012 vp/day (3 units) for patients with one lesion with a maximum diameter >10 cm or ≥ three lesions; (4) for patients with two or more lesions, the dose of H101 for each lesion was further decided by the proportion and size of the different lesions. The number of cycles of H101 was determined according to the instructions for the use of H101 and patients’ effect after injection. After injection of H101, renin (0.1 mg/ml) and thrombin (10-100 unit/mL) were sprayed to stop the bleeding”.
Thirdly, the statistical comparison of CR and PD between group A and group C was incorrectly stated. A correction has been made to
“Whereas, the combination of H101 injection with chemotherapy in group C (
Short-term outcomes of H101, chemotherapy, and H101 combined with chemotherapy for advanced gastric carcinoma.
| Group A ( |
Group B ( |
Group C ( |
|
|
|---|---|---|---|---|
| Response assessment after treatment | ||||
| Complete response | 1 (3.3%) | 2 (6.1%) | 4 (12.5%)* | 0.022 |
| Partial response | 8 (26.7%) | 9 (27.3%) | 12 (37.5%) | 0.168 |
| Stable disease | 10 (33.3%) | 11 (33.3%) | 10 (31.3%) | 0.941 |
| Progressive diseases | 11 (36.7%) | 11 (33.3%) | 6 (18.7%)* | 0.014 |
| Disease control rate | 19 (63.3%) | 22 (66.7%) | 26 (81.3%)* | 0.014 |
| Overall response rate | 9 (30.0%) | 11 (33.3%) | 16 (50.0%)* | 0.007 |
Group A, H101; Group B, chemotherapy; Group C, H101 combined with chemotherapy. *p < 0.05 compared with group A.
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.